Stocktoria
LENSAR, Inc. LNSR
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2020-09-21
LENSAR, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $58.4M | $53.5M | $42.2M | $35.4M | $34.5M |
| R&D expense | $5.6M | $5.3M | $6.1M | $11.8M | $12.4M |
| SG&A expense | $45.2M | $26.5M | $26.1M | $27.2M | $23.9M |
| Operating income | -$24.6M | -$10.7M | -$12.2M | -$20.2M | -$19.7M |
| Net income | -$34.3M | -$31.4M | -$14.4M | -$19.9M | -$19.6M |
| EPS (diluted) | $-2.87 | $-2.73 | $-1.31 | $-1.96 | $-2.09 |
| Operating cash flow | -$14.8M | -$2.3M | -$9.7M | -$14.9M | -$9.0M |
| Free cash flow | -$14.9M | -$2.4M | -$9.9M | -$15.0M | -$9.3M |
| Cash & equivalents | $13.0M | $16.3M | $20.6M | $14.7M | $31.6M |
| Inventory | $21.5M | $11.4M | $15.7M | $11.7M | $6.5M |
| Total assets | $71.4M | $66.3M | $69.6M | $55.8M | $66.5M |
| Total liabilities | $83.7M | $47.7M | $22.4M | $13.9M | $11.6M |
| Shareholders' equity | -$26.0M | $4.9M | $33.4M | $42.0M | $54.9M |
Source: SEC EDGAR filings · CIK 0001320350 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.